UA93349C2 - Способ стабилизации мономерного белка интерферона - Google Patents

Способ стабилизации мономерного белка интерферона

Info

Publication number
UA93349C2
UA93349C2 UAA200612403A UAA200612403A UA93349C2 UA 93349 C2 UA93349 C2 UA 93349C2 UA A200612403 A UAA200612403 A UA A200612403A UA A200612403 A UAA200612403 A UA A200612403A UA 93349 C2 UA93349 C2 UA 93349C2
Authority
UA
Ukraine
Prior art keywords
monomeric protein
bulk
stabilizing interferon
excipient
interferon
Prior art date
Application number
UAA200612403A
Other languages
English (en)
Ukrainian (uk)
Inventor
Амер Джабер
Original Assignee
Эйрэс Трейдинг C.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйрэс Трейдинг C.A. filed Critical Эйрэс Трейдинг C.A.
Publication of UA93349C2 publication Critical patent/UA93349C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Abstract

Изобретение касается способа получения стабилизированного неразбавленного раствора мономерного белка - бета-интерферона, который заключается в обеспечении наличия основной массы мономерного белка в буферном растворе и добавлении наполнителя к основной массе, причем наполнитель выбран из группы, которая включает бактериостатические препараты, поверхностно-активные вещества, агенты для регулирования изотоничности, аминокислоты, антиоксиданты и их комбинации.
UAA200612403A 2004-06-01 2005-05-27 Способ стабилизации мономерного белка интерферона UA93349C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04076627 2004-06-01

Publications (1)

Publication Number Publication Date
UA93349C2 true UA93349C2 (ru) 2011-02-10

Family

ID=34928262

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200612403A UA93349C2 (ru) 2004-06-01 2005-05-27 Способ стабилизации мономерного белка интерферона

Country Status (17)

Country Link
US (1) US7858082B2 (ru)
EP (1) EP1750750B1 (ru)
JP (1) JP2008500995A (ru)
CN (1) CN1993138B (ru)
AT (1) ATE543506T1 (ru)
AU (1) AU2005249232B2 (ru)
BR (1) BRPI0510527A (ru)
CA (1) CA2567309A1 (ru)
EA (1) EA012281B1 (ru)
ES (1) ES2381674T3 (ru)
HK (1) HK1102561A1 (ru)
IL (1) IL179617A0 (ru)
MX (1) MXPA06014079A (ru)
NO (1) NO20065861L (ru)
UA (1) UA93349C2 (ru)
WO (1) WO2005117948A1 (ru)
ZA (1) ZA200610041B (ru)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1660531A2 (en) 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
BRPI0710826A2 (pt) * 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US10047354B2 (en) 2007-08-24 2018-08-14 Novo Nordisk Health Care Ag Reduction of dimer content in factor VII polypeptide compositions by heat treatment
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SI2234645T1 (sl) * 2007-12-20 2012-07-31 Merck Serono Sa Formulacije peg interferon beta
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010045168A1 (en) 2008-10-16 2010-04-22 Andrew Desbarats Method and apparatus for producing alcohol or sugar using a commercial-scale bioreactor
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010049488A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010057259A1 (en) * 2008-11-19 2010-05-27 James Cook University Protein stability assay using a fluorescent reporter of protein folding
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2498801B1 (de) * 2009-11-13 2018-01-24 Sanofi-Aventis Deutschland GmbH HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
NZ609469A (en) 2010-11-11 2015-02-27 Abbvie Biotechnology Ltd Improved high concentration anti-tnfα antibody liquid formulations
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103271871A (zh) * 2013-03-18 2013-09-04 长春海伯尔生物技术有限责任公司 一种重组人干扰素注射液及其制备方法
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
KR20200089282A (ko) * 2017-11-20 2020-07-24 저스트-에보텍 바이오로직스, 아이엔씨. 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
CN1222315C (zh) * 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
PT1224940E (pt) * 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
SI1421956T1 (sl) 1998-04-28 2007-10-31 Serono Lab Postopek za stopenjsko vezavo polietilenglikola (peg) na polipeptid
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003002152A2 (en) * 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
AU2003268664A1 (en) * 2002-09-26 2004-04-19 Shionogi And Co., Ltd. Stabilized protein compositions
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations

Also Published As

Publication number Publication date
EA200602254A1 (ru) 2007-06-29
US20070244299A1 (en) 2007-10-18
WO2005117948A1 (en) 2005-12-15
ZA200610041B (en) 2008-07-30
IL179617A0 (en) 2007-05-15
EP1750750A1 (en) 2007-02-14
AU2005249232A1 (en) 2005-12-15
EA012281B1 (ru) 2009-08-28
ATE543506T1 (de) 2012-02-15
CN1993138A (zh) 2007-07-04
US7858082B2 (en) 2010-12-28
CN1993138B (zh) 2010-12-15
EP1750750B1 (en) 2012-02-01
CA2567309A1 (en) 2005-12-15
BRPI0510527A (pt) 2007-10-30
AU2005249232B2 (en) 2010-08-05
ES2381674T3 (es) 2012-05-30
MXPA06014079A (es) 2007-02-15
NO20065861L (no) 2007-03-01
JP2008500995A (ja) 2008-01-17
HK1102561A1 (en) 2007-11-30

Similar Documents

Publication Publication Date Title
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
NO2017027I1 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
EA200602137A1 (ru) Гидрогелевые препараты интерферона
EA200602257A1 (ru) Стабилизированные жидкие препаративные формы интерферона
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
DE60204714D1 (de) Pharmakologische nahrungszusammensetzung zur nahrungsergängzung und nährwertverbesserung
EP1536828A4 (en) PROCESS FOR THE ADDITION OF EXOGENOUS PROTEINS IN THE ZYTOSOL AND USES THEREOF
EA200800327A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сыворотный альбумин
GB0010314D0 (en) Anti-freeze proteins their production and use
TW200735781A (en) Food product
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
SG142165A1 (en) Biologically active peptides
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
HK1076735A1 (en) Antigen-specific ige antibody production inhibitors
AU2003282159A8 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
WO2005058229A3 (en) Antiviral proteins with improved properties and methods therefor
MY142798A (en) Methods for preventing glyconoylation of proteins
DE10394174D2 (de) Peptide mit hohem Cysteingehalt
WO2003104390A3 (en) ADUCTIVE NUCLEIC ACIDS AND PROTEINS